Biomarin Pharmaceutical (BMRN) Other Non-Current Liabilities (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Other Non-Current Liabilities data on file, last reported at $155.5 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 19.89% year-over-year to $155.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $155.5 million (up 19.89% YoY) and the FY2025 annual result came in at $150.8 million, up 17.07% from the prior year.
• Other Non-Current Liabilities improved to $155.5 million in Q1 2026, from $150.8 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $163.1 million in Q3 2025 to a low of $92.4 million in Q1 2023.
• A 5-year average of $120.3 million and a median of $119.4 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 559.43% — and 2023, when it slipped 8.42%.
• Tracing BMRN's Other Non-Current Liabilities over 5 years: stood at $100.0 million in 2022, then grew by 19.92% to $119.9 million in 2023, then gained by 7.41% to $128.8 million in 2024, then rose by 17.07% to $150.8 million in 2025, then rose by 3.09% to $155.5 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $155.5 million (Q1 2026), $150.8 million (Q4 2025), and $163.1 million (Q3 2025), per Business Quant data.